Pipeline
Biosion is committed to developing therapies that will have significant impact in treating immune and oncologic diseases.
Our best-in-class and first-in-class portfolio is designed to address significant unmet medical needs through the development of mono and bi-specific protein therapeutics, antibody drug conjugates and macrophage stimulating agents for patients worldwide.
A Diversified Portfolio with Global Velocity
Patient-centric focus is integral to Biosion’s R&D strategy
Portfolio of global competitiveness with meaningful differentiation
Pipeline Assets Entering Phase I in 2021 and 2022
Drag table right
PROGRAM (TARGET)
POTENTIAL INDICATION(S)
PRE-CLINICAL
IND
PHASE I
PARTNERS
